Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study

Radiotherapy and Oncology

Volumn 83, Issue 3, 2007, Pages 383-388

  Eriksen, Jesper Grau ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CA IX; Head and neck cancer; Hypoxia; Nimorazole; Prognostic marker; Radiotherapy

Indexed keywords

CARBONATE DEHYDRATASE IX; FORMALDEHYDE; NIMORAZOLE; PARAFFIN; RADIOSENSITIZING AGENT;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STAINING;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELLS, CULTURED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NIMORAZOLE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION-SENSITIZING AGENTS;

EID: 34250182435     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.05.009     Document Type: Article

References (21)

1. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14 (2004) 198-206
2. Horsman M.R., and Overgaard J. The oxygen effect and tumour microenviroment. In: Steel G.G. (Ed). Basic clinical radiobiology (2002), Arnold, London 158-168
3. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
4. Horsman M.R. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 42 (1998) 701-704
5. Hoogsteen I.J., Marres H.A., Bussink J., van der Kogel A.J., and Kaanders J.H. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck 29 (2007) 591-604
6. Bussink J., Kaanders J.H., and van der Kogel A.J. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67 (2003) 3-15
7. Potter C., and Harris A.L. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3 (2004) 164-167
8. Beasley N.J., Wykoff C.C., Watson P.H., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61 (2001) 5262-5267
9. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
10. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61 (2001) 6394-6399
11. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
12. Jonathan R.A., Wijffels K.I., Peeters W., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79 (2006) 288-297
13. De S.H., Landuyt W., Verbeken E., Goethals L., Hermans R., and Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy. BMC Cancer 5 (2005) 42
14. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8 (2002) 2595-2604
15. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
16. Hoogsteen I.J., Marres H.A., Wijffels K.I., et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 11 (2005) 97-106
17. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764
18. Nordsmark M., Eriksen J.G., Gebski V., Alsner J., Horsman M.R., and Overgaard J. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83 (2007) 389-397
19. Cairns R., Papandreou I., and Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4 (2006) 61-70
20. Sorensen B.S., Hao J., Overgaard J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 (2005) 187-193
21. Troost E.G., Bussink J., Kaanders J.H., et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 76 (2005) 194-199